Tarsus Pharmaceuticals (TARS) Capital Expenditures (2019 - 2026)

Tarsus Pharmaceuticals' Capital Expenditures history runs 8 years deep, the most recent figure standing at $911000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 54.41% year-over-year to $911000.0 in Q1 2026; TTM through Mar 2026 was $10.2 million, a 413.36% increase from a year earlier, with the FY2025 full-year figure at $9.9 million, up 529.16% from the prior year.
• Capital Expenditures retreated to $911000.0 in Q1 2026 per TARS's latest filing, from $8.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $8.4 million in Q4 2025 and bottomed at -$784000.0 in Q4 2023.
• The 5-year median for Capital Expenditures is $257000.0 (2023), against an average of $829375.0.
• Across the five-year window, Capital Expenditures slumped 660.0% in 2023 and surged 454.01% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $140000.0 in 2022, then slumped by 660.0% to -$784000.0 in 2023, then jumped by 292.47% to $1.5 million in 2024, then jumped by 454.01% to $8.4 million in 2025, then tumbled by 89.1% to $911000.0 in 2026.
• Per Business Quant, the three latest TARS Capital Expenditures figures stand at $911000.0 (Q1 2026), $8.4 million (Q4 2025), and -$92000.0 (Q3 2025).